To contact Medical Information about our products or report an adverse event, click here.
Takeda’s top priority is the health of Canadians. Their well-being is central to our work and drives our commitment to deliver a diverse portfolio of innovative treatments.
Current important medicines available to Canadians from Takeda Canada include:
For legacy Shire product information, click here:
https://www.takeda.com/en-ca/what-we-do/our-medicines/shire-products
PRODUCTS |
|
ADDERALL XR® mixed salts amphetamine |
|
ALUNBRIG™ brigatinib |
|
CINRYZE® C1 inhibitor [human] |
|
DEXILANT® dexlansoprazole |
Product Monograph |
ENTYVIO® vedolizumab |
Product Monograph |
FIRAZYR® icatibant injection |
Product Monograph |
INTUNIV XR® guanfacine hydrochloride |
Product Monograph |
KAZANO® alogliptin (as alogliptin benzoate) and metformin hydrochloride |
Product Monograph |
NESINA® alogliptin (as alogliptin benzoate) |
Product Monograph |
NINLARO® ixazomib (as ixazomib citrate) |
Product Monograph |
OBIZUR® Antihemophilic Factor (Recombinant), Porcine Sequence |
Product Monograph |
ONDISSOLVE® ODF ondansetron |
Product Monograph |
PANTOLOC® pantoprazole sodium |
Product Monograph |
REVESTIVE® Teduglutide for injection |
Product Monograph |
TECTA® pantoprazole magnesium |
Product Monograph |
ULORIC® febuxostat |
Product Monograph Health Product Risk Communication (November 2019) |
VPRIV® velaglucerase alfa |
Product Monograph |
VYVANSE® lisdexamfetamine dimesylate |
Product Monograph |